NANOG is a specific biomarker predicting malignant transformation of proliferative verrucous leukoplakia

Yanning Zhang, Xinning Zhang, Yanting Chi, Jiayin Song, Long Li, Binbin LiResearch Square 2025 · DOI

Abstract

Background: Proliferative verrucous leukoplakia (PVL) is a special type of oral leukoplakia with no unified diagnosis criteria. Objective: To evaluate the diagnostic values of NANOG for PVL and explore the associations between NANOG expression and the malignant transformation of PVL. Methods: A total of 112 patients were collected, including 79 cases of PVL (48 cases developed into oral squamous cell carcinoma) and 33 patients diagnosed as conventional oral leukoplakia (COL). The expression of NANOG was detected by immunohistochemical staining. Results: NANOG showed higher expression in 34 cases (70.83%) of PVL with malignant transformation, significantly higher than that in PVL without malignant transformation and COL (P < 0.05). NANOG expression correlated with non-homogeneous clinical manifestation and oral epithelial dysplasia (P < 0.001). ROC analysis revealed its utility in identifying PVL from COL (AUC = 0.674) and predicting malignant transformation (AUC = 0.806, sensitivity 0.900, specificity 0.903). Kaplan-Meier data revealed that patients with high NANOG expression had shorter malignant transformation-free survival (P < 0.001). Multivariate COX analysis confirmed high NANOG expression as an independent risk factor. Conclusions: NANOG is a promising diagnostic and prognostic biomarker for PVL.

Introduction

Oral cancer often begins as leukoplakia—white patches in the mouth. While most are benign, Proliferative Verrucous Leukoplakia (PVL) is a rare, aggressive subtype notorious for recurring and transforming into oral squamous cell carcinoma (OSCC). PVL is a "diagnostic chameleon," often appearing identical to conventional oral leukoplakia (COL) in early stages. Current diagnosis relies on subjective history and oral epithelial dysplasia (OED), yet many PVL cases turn cancerous without showing dysplasia. This study investigates NANOG, a protein associated with stem cell pluripotency, as a potential molecular marker to identify high-risk patients early.

Methods

The researchers conducted a nested case-control study using tissue samples from 112 patients (79 PVL, 33 COL). They employed immunohistochemical (IHC) staining to measure NANOG expression. Statistical tools included ROC analysis for diagnostic accuracy, Kaplan-Meier analysis for transformation-free survival, and Multivariate COX Regression to determine if NANOG is an independent risk factor. Results were validated using an external cohort of 31 patients.

Results

NANOG expression was significantly higher in PVL cases that progressed to cancer compared to non-transforming cases and COL controls.

Table 1: Baseline characteristics and NANOG expression levels in PVL and COL cohorts.

Key findings include:

  • High Correlation: 70.83% of transforming PVL cases showed high NANOG expression.
  • Predictive Power: NANOG achieved an AUC of 0.806 for predicting malignant transformation, with high sensitivity (0.900) and specificity (0.903).
  • Survival Impact: High NANOG expression was linked to significantly shorter cancer-free survival times (P < 0.001).
  • Independent Risk: Multivariate analysis confirmed NANOG as an independent risk factor, providing predictive value beyond age or smoking history.

Discussion

NANOG is a transcription factor that maintains stem cell pluripotency. Its presence in oral lesions suggests cells are reverting to a primitive, "stem-like" state—a hallmark of early cancer development. Interestingly, NANOG levels were high in early PVL stages before cancer appeared but did not change significantly once cancer developed, suggesting it acts as a "trigger" for transformation. Crucially, NANOG outperformed the current gold standard (OED) in predicting cancer, filling a critical gap for PVL cases that lack dysplasia but remain high-risk.

Conclusion

NANOG is a promising diagnostic and prognostic biomarker for PVL. While larger multi-center studies are needed, these results suggest that IHC staining for NANOG could help clinicians identify high-risk lesions earlier and potentially serve as a target for future gene-targeted preventive therapies.

Summary updated

Abstract

<title>Abstract</title> <bold>Background: </bold>Proliferative verrucous leukoplakia (PVL) is a special type of oral leukoplakia with no unified diagnosis criteria. <bold>Objective:</bold> To evaluate the diagnostic values of NANOG for PVL and explore the associations between NANOG expression and the malignant transformation of PVL. <bold>Methods: </bold>A total of 112 patients were collected, including 79 cases of PVL (48 cases developed into oral squamous cell carcinoma) and 33 patients diagnosed as conventional oral leukoplakia (COL). The expression of NANOG was detected by immunohistochemical staining. <bold>Results:</bold> NANOG showed higher expression in 34 cases(70.83%) PVL with malignant transformation, significantly higher than that in PVL without malignant transformation and COL (<italic>P</italic>&lt;0.05), and the NANOG expression was correlated with non-homogeneous clinical manifestation and oral epithelial dysplasia (<italic>P</italic>&lt;0.001). Receiver operating characteristic (ROC) analysis revealed that it would be used to identify PVL from COL, AUC = 0.674, with sensitivity and specificity of 0.800 and 0.879. Kaplan-Meier plotter data revealed that patients with high NANOG expression had shorter malignant transformation-free survival than those with low expression (<italic>P</italic>&lt;0.001). Multivariate COX analysis further confirmed that high NANOG expression was an independent risk factor for malignant transformation of PVL. ROC analysis also revealed that it would be used to predict the malignant transformation of PVL, AUC = 0.806, with sensitivity and specificity of 0.900 and 0.903. The above resultswere also validated in external case cohort. <bold>Conclusions: </bold>NANOG would be a promising diagnostic and prognostic biomarker for PVL.
BibTeX
@inproceedings{zhang2025nanog,
  author = {Yanning Zhang and Xinning Zhang and Yanting Chi and Jiayin Song and Long Li and Binbin Li},
  title = {{NANOG is a specific biomarker predicting malignant transformation of proliferative verrucous leukoplakia}},
  booktitle = {Research Square},
  year = {2025},
  doi = {10.21203/rs.3.rs-7191114/v1},
}
Figure